Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[HIV infection 2007].

Anja Potthoff1, Norbert Brockmeyer,

  • 1Klinik für Dermatologie und Allergologie der Ruhr-Universität Bochum, St. Josef-Hospital, Bochum, Germany.

Medizinische Klinik (Munich, Germany : 1983)
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term intraanal HPV16 infection in men having sex with men with HIV: Persistence or reinfection?

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.

AIDS (London, England)·2026
Same author

HPV knowledge and acceptance of HPV vaccination among men who have sex with men (MSM) in Germany: a multicenter, observational, cross-sectional study.

BMC public health·2025
Same author

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b study.

EClinicalMedicine·2025
Same author

Safety and efficacy of monoclonal antibody therapy in patients with chronic herpes simplex virus-2 genital infections: MATCH-2, a randomized double-blinded, parallel-group phase 2 multi-center trial.

Pharmacological research·2025
Same author

Optimizing Immunization Strategies for Individuals Living with HIV: A Review of Essential Vaccines, Vaccine Coverage, and Adherence Factors.

Vaccines·2025
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

Antiretroviral therapy has dramatically advanced HIV treatment, with new drugs effective against resistant strains. Early treatment initiation is crucial for preventing new infections and improving patient outcomes.

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Context:

  • Significant advancements in Human Immunodeficiency Virus (HIV) treatment.
  • Approval of 19 antiretroviral substances in Germany.
  • Emergence of new therapeutic classes like CCR5 antagonists and integrase inhibitors.

Purpose:

  • To review recent developments in HIV treatment.
  • To discuss the efficacy of new antiretroviral agents.
  • To highlight ongoing challenges and the importance of treatment timing.

Summary:

  • New antiretroviral drugs demonstrate effectiveness against multidrug-resistant HIV strains.
  • CCR5 antagonists and integrase inhibitors offer new options for treatment-experienced patients.
  • Despite progress, challenges such as metabolic and cardiovascular complications persist.

Related Experiment Videos

Impact:

  • Early HIV treatment initiation is recommended to prevent further transmission and improve disease progression.
  • Ongoing research is necessary to address long-term side effects and optimize therapeutic strategies.
  • The evolving landscape of HIV therapy requires continuous evaluation of treatment initiation and management.